Tasquinimod

Drug Profile

Tasquinimod

Alternative Names: ABR-215050; TASQ

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; Ipsen
  • Class Antineoplastics; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Calgranulin B modulators; Immunomodulators; Thrombospondin 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma; Prostate cancer

Highest Development Phases

  • Suspended Multiple myeloma
  • Discontinued Gastric cancer; Hepatocellular carcinoma; Ovarian cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 15 Nov 2017 Tasquinimod is available for licensing as of 09 Nov 2017. http://www.activebiotech.com/project-overview
  • 28 Aug 2017 Ipsen completes the phase II Umbrella trial for Renal cancer, Ovarian cancer, Gastric cancer & Hepatocellular carcinoma (Metastatic disease, Late-stage disease, Second-line therapy or greater) in United Kingdom, France, Belgium, Spain and Canada (PO)
  • 02 Jun 2017 Additional efficacy data from a phase III trial in Prostate cancer presented at the American Society of Clinical Oncology Annual Meeting (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top